source
- Latigo Biotherapeutics raises $345.6M in IPO to fund non-opioid pain drug pipelineLatigo Biotherapeutics, a Los Angeles-based biotech focused on non-opioid ion-channel-blocking pain therapies, completed an initial public offering on Thursday. The company sold 19.2 million share…
- FDA outlines inspection overhaul, proposes IND reforms, and greenlights a disputed cancer therapyFDA officials announced a plan to restructure the agency’s inspectional operations, aiming to make inspections more efficient and focused. The proposed changes include consolidating regional office…